HOME >> BIOLOGY >> NEWS
Vion's TAPET® administered to first patients in Phase I human intratumoral safety trial at the Cleveland Clinic Foundation

NEW HAVEN, CONN., DECEMBER 8, 1999 -- VION PHARMACEUTICALS, INC. (NASDAQ NM: VION) today announced that VNP20009, the company's first generation TAPET® bacterial vector, has been administered to the first patients enrolled into Vion's Phase I intratumoral trial, which is being conducted at The Cleveland Clinic Foundation. The patients were initially monitored in the hospital and subsequently discharged. Potential safety and efficacy will continue to be monitored according to the protocol. The Phase I study is designed to evaluate the safety, potential efficacy and optimum biological dose of an intratumoral administration for patients with either cutaneous or subcutaneous solid tumors. Patients will be evaluated for the accumulation of VNP20009 in the tumor and non-injected lesions. Patient accrual continues for this trial, which may involve up to 20-30 patients.

TAPET (Tumor Amplified Protein Expression Therapy), Vion's core platform technology, are highly attenuated bacteria that, in preclinical studies, have demonstrated preferential replication in tumors compared to normal tissues. The bioengineered bacteria have demonstrated an excellent safety profile in preclinical toxicology studies. Preferential replication allows the bacteria to produce and deliver a variety of anti-cancer therapeutic products at high concentrations to tumors while minimizing toxicity to normal tissues. By bringing the "drug factory" preferentially to the tumor, Vion believes that TAPET may result in a cancer therapy that is more concentrated, more effective and less toxic to normal tissue. Furthermore, the unarmed bacteria by themselves have shown good anti-tumor activity in animal models. Vion plans to develop the unarmed TAPET alone as an anti-tumor agent and to develop second-generation products that produce and deliver potent therapeutic anti-cancer agents.

Vion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the research, development and commerci
'"/>

Contact: Sue Yeoh
syeoh@cpronline.com
201-641-2408 x43
Vion Pharmaceuticals, Inc.
8-Dec-1999


Page: 1 2

Related biology news :

1. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. Newly identified master gene key in babys first breath
4. The book opens on the first tree genome
5. DuPont developing new protective suits for military, first responders
6. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
7. Maine-based biophysics institute gets funding for first US-based 4Pi nanoscale microscope
8. Veterinarians discover first known case of canine distemper in a wild tiger
9. Study reveals first genetic step necessary for prostate cancer growth
10. The first engineering of cell surfaces in living animals
11. Infant rats eagerly accept high concentrations of alcohol upon first exposure

Post Your Comments:
(Date:5/23/2013)... per year, carrying more than 284 million tons of cargo, ... dollars in toll fees for the Panama Canal Authority. Each ... of water are used from Gatun Lake, which is also ... in the isthmus. , However, the advent of very ... the ships at sea, has demanded change. The Panama Canal ...
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... Given the implications for the overall health, development, ... a primary role in ensuring that all students ... minutes per day of vigorous or moderate-intensity physical ... of Medicine. Recent estimates suggest that only ... guideline for promoting better health and development. ...
Breaking Biology News(10 mins):Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3
(Date:5/23/2013)... May 23, 2013 Watlow®, an ... complete thermal systems, recently introduced its new catalog, ... of experience in designing and manufacturing industrial heaters, ... products to serve diverse customer needs. , A ... at the beginning of the book. These options ...
(Date:5/22/2013)... Industry leaders from around the ... Oak Ridge National Laboratory’s Biosurveillance Symposium ... the Hilton Alexandria Mark Center. Held in conjunction ... conference on June 18 - 19. , Join ... Elements, Applied Research Associates, ARA, AttaGene, Battelle, Benedictine ...
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Genedata, ... industrial biotechnology, drug discovery, and life science research, ... Selector ™ as its bioinformatics platform for ... organisms. Genedata will provide AB Enzymes, one of ... a hosted solution of Genedata Selector accompanied by ...
Breaking Biology Technology:Watlow Introduces Its New Industrial Heater Catalog 2Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 2Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 3Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 4Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 5Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4
Cached News: